Sintilimab as adjuvant therapy for patients with resected HCC at high risk of recurrence

被引：0
|
作者：
Hindson, Jordan
机构：
[1] Nature Reviews Gastroenterology & Hepatology,
来源：
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY | 2024年 / 21卷 / 03期
关键词：
D O I：
10.1038/s41575-024-00904-5
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：141 / 141
页数：1
相关论文
共 50 条
  • [1] Sintilimab as adjuvant therapy for patients with resected HCC at high risk of recurrence
    Jordan Hindson
    Nature Reviews Gastroenterology & Hepatology, 2024, 21 : 141 - 141
  • [2] Adjuvant sintilimab effective in high-risk HCC
    Sidaway, Peter
    NATURE REVIEWS CLINICAL ONCOLOGY, 2024, 21 (03) : 168 - 168
  • [3] Adjuvant sintilimab effective in high-risk HCC
    Sidaway P.
    Nature Reviews Clinical Oncology, 2024, 21 (3) : 168 - 168
  • [4] Adjuvant therapy for resected high-risk melanoma
    Moser, Justin C.
    Grossmann, Kenneth F.
    SEMINARS IN CUTANEOUS MEDICINE AND SURGERY, 2018, 37 (02) : 109 - 111
  • [5] Adjuvant ICIs Plus Targeted Therapies Reduce HCC Recurrence after Hepatectomy in Patients with High Risk of Recurrence
    Yang, Jianming
    Jiang, Shijie
    Chen, Yewu
    Zhang, Jian
    Deng, Yinan
    CURRENT ONCOLOGY, 2023, 30 (02) : 1708 - 1719
  • [6] Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial
    Wang, Kang
    Xiang, Yan-Jun
    Yu, Hong-Ming
    Cheng, Yu-Qiang
    Liu, Zong-Han
    Qin, Ying-Yi
    Shi, Jie
    Guo, Wei-Xing
    Lu, Chong-De
    Zheng, Ya-Xin
    Zhou, Fei-Guo
    Yan, Mao-Lin
    Zhou, Hong-Kun
    Liang, Chao
    Zhang, Fan
    Wei, Wen-Jing
    Lau, Wan Yee
    Li, Jing-Jing
    Liu, Yan-Fang
    Cheng, Shu-Qun
    NATURE MEDICINE, 2024, 30 (03) : 708 - +
  • [7] Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial
    Kang Wang
    Yan-Jun Xiang
    Hong-Ming Yu
    Yu-Qiang Cheng
    Zong-Han Liu
    Ying-Yi Qin
    Jie Shi
    Wei-Xing Guo
    Chong-De Lu
    Ya-Xin Zheng
    Fei-Guo Zhou
    Mao-Lin Yan
    Hong-Kun Zhou
    Chao Liang
    Fan Zhang
    Wen-Jing Wei
    Wan Yee Lau
    Jing-Jing Li
    Yan-Fang Liu
    Shu-Qun Cheng
    Nature Medicine, 2024, 30 : 708 - 715
  • [8] Durvalumab with or without bevacizumab as adjuvant therapy for HCC patients at risk of recurrence after curative therapy: EMERALD-2
    Galle, P. R.
    Knox, J.
    Lencioni, R.
    Cheng, A. -L.
    Cleary, S.
    Kokudo, N.
    Park, J. -W.
    Zhou, J.
    He, P.
    Morgan, S.
    Cohen, G.
    Fan, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 123 - 124
  • [9] A randomized phase II trial of epigenetic therapy following adjuvant treatment in patients with resected pancreatic cancer and high risk for recurrence.
    Reiss, Kim Anna
    Ahuja, Nita
    Baylin, Stephen
    Mauro, Lauren Ann
    Linden, Sheila
    White, Sharon
    Laheru, Daniel A.
    Herman, Joseph M.
    Wolfgang, Christopher Lee
    Weiss, Matthew J.
    Cameron, John L.
    Makary, Martin
    Azad, Nilofer Saba
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [10] Adjuvant therapy for high-risk primary and resected metastatic melanoma
    Hersey, P
    INTERNAL MEDICINE JOURNAL, 2003, 33 (1-2) : 33 - 43
12345